Trial reportHypertension (Dallas, Tex. : 1979)2020
Incidence and Implications of Atrial Fibrillation/Flutter in Hypertension: Insights From the SPRINT Trial.
Trial report in Hypertension (Dallas, Tex. : 1979), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Orthostatic Systolic Blood Pressure Elevation and Incident Atrial Fibrillation: Insights From the SPRINT Trial.Journal of clinical hypertension (Greenwich, Conn.) · 2025Trial
- Association Between Visit-to-Visit Blood Pressure Variability and Incidence of Atrial Fibrillation in Hypertensive Patients: A Post-Hoc Analysis of the SPRINT Trial.Journal of clinical hypertension (Greenwich, Conn.) · 2025Trial
- Genetic European Ancestry and Incident Diabetes in Black Individuals: Insights From the SPRINT Trial.Circulation. Genomic and precision medicine · 2022Trial
- Obesity and Serial NT-proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE-IT Trial.Journal of the American Heart Association · 2021Trial
- Atrial Fibrillation Risk Management and Emerging Therapies.Journal of clinical medicine · 2026Review
- Article
- New-onset hypertension as a contributing factor to the incidence of atrial fibrillation in the elderly.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Aggravated Gut Microbiota and Metabolomic Imbalances Are Associated with Hypertension Patients Comorbid with Atrial Fibrillation.Biomolecules · 2022Article
- Association of Pathogenic DNA Variants Predisposing to Cardiomyopathy With Cardiovascular Disease Outcomes and All-Cause Mortality.JAMA cardiology · 2022Article
- Hypertension and Arrhythmias: A Clinical Overview of the Pathophysiology-Driven Management of Cardiac Arrhythmias in Hypertensive Patients.Journal of cardiovascular development and disease · 2022Review
- Latest hypertension research to inform clinical practice in Asia.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Risk-Based Intensive Blood Pressure Lowering and Prevention of Heart Failure: A SPRINT Post Hoc Analysis.Hypertension (Dallas, Tex. : 1979) · 2021Article
- Left heart function evaluation of patients with essential hypertension and paroxysmal atrial fibrillation by two-dimensional speckle tracking imaging combined with real-time three-dimensional ultrasound imaging.Journal of thoracic disease · 2021Article
- What Is the Ideal Blood Pressure Treatment Target for Primary Prevention and Management of Atrial Fibrillation?Frontiers in cardiovascular medicine · 2020Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
We evaluated the impact of intensive blood pressure control on the incidence of new-onset atrial fibrillation/flutter (AF) and the prognostic implications of preexisting and new-onset AF in SPRINT (Systolic Blood Pressure Intervention Trial) participants. New-onset AF was defined as occurrence of AF in 12-lead electrocardiograms after randomization in participants free of AF at baseline. Poisson regression modeling was used to calculate incident rates of new-onset AF. Multivariable-adjusted Cox proportional hazard models were used to evaluate the risk of adverse cardiovascular events (composite of myocardial infarction, non-myocardial infarction acute coronary syndrome, stroke, heart failure, or cardiovascular death). In 9327 participants, 8.45% had preexisting AF, and 1.65% had new-onset AF. The incidence of new-onset AF was 4.53 per 1000-person years, with similar rates in the standard and intensive treatment arms (4.95 versus 4.11 per 1000-person years; adjusted
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.